e-learning
resources
2019
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions
Karlijn Hummelink, Mirte Muller, Theodora C. Linders, Vincent van der Noort, Petra M. Nederlof, Paul Baas, Sjaak Burgers, Egbert F. Smit, Gerrit A. Meijer, Michel M. van den Heuvel, Daan van den Broek, Kim Monkhorst
Source:
ERJ Open Res, 5 (1) 00016-2019; 10.1183/23120541.00016-2019
Journal Issue:
February
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Karlijn Hummelink, Mirte Muller, Theodora C. Linders, Vincent van der Noort, Petra M. Nederlof, Paul Baas, Sjaak Burgers, Egbert F. Smit, Gerrit A. Meijer, Michel M. van den Heuvel, Daan van den Broek, Kim Monkhorst. Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions. ERJ Open Res, 5 (1) 00016-2019; 10.1183/23120541.00016-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
The inhibitory effect of PI3k inhibitor and MEK inhibitor on malignant pleural mesothelioma cell growth
Source: Annual Congress 2009 - Pleural and mediastinal diseases
Year: 2009
Inhibition of phosphatidylinositol 3-kinase and mitogen-activated protein kinase kinase prevents malignant pleural mesothelioma cell growth
Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology
Year: 2010
Mice deficient in Raf kinase inhibitor protein (RKIP) have elevated indices of pulmonary hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
The predictive value of circulating tumor DNA dynamics in plasma of EGFR-mutation-positive NSCLC patients on first line tyrosine kinase inhibitors
Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer
Year: 2021
Cough and hypereosinophilia due to FIP1L1-PDGFRA fusion gene with tyrosine kinase activity
Source: Eur Respir J 2006; 27: 230-232
Year: 2006
Uncommon EGFR mutations of lung adenocarcinoma in one tertiary institution, Korea: clinical characteristics and treatment response to tyrosine kinase inhibitors
Source: International Congress 2018 – Lung cancer: from the bench to the bedside
Year: 2018
Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells
Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer
Year: 2020
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors
Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020
Year: 2020
Antitumor activity of MEK and PI3K inhibitors in malignant pleural mesothelioma
Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma
Year: 2011
The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD
Source: Annual Congress 2008 - Novel treatments for respiratory disease
Year: 2008
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer
Source: Eur Respir J 2012; 39: 677-684
Year: 2012
Constitutive phosphorylation of p38 mitogen activated protein kinase controls proliferation of mesothelioma cells
Source: Eur Respir J 2005; 26: Suppl. 49, 225s
Year: 2005
Epidermal growth factor receptor (EGFR) gene mutation testing prior to tyrosine kinase inhibitors (TKI) treatment – prospective data from the Czech TULUNG registry
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020
The effect of smoking on phosphoinositide 3-kinase (PI3K) and phosphatase and tensin homolog deleted from chromosome 10 (PTEN) mRNA expression in human airway epithelial cells
Source: International Congress 2014 – Mechanistic studies of the airway epithelium
Year: 2014
A patient with a lazarus effect on tyrosine kinase inhibition
Source: Virtual Congress 2020 – Lung cancer grand round
Year: 2020
mTOR inhibition blocks tumor growth and pleural fluid accumulation in experimental murine mesothelioma
Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma
Year: 2011
The proteasome inhibitor bortezomib is effective against experimental malignant pleural effusion
Source: Annual Congress 2008 - Novel targets in the molecular pathology of lung cancer and COPD
Year: 2008
Validation of AMP-activated protein kinase as a therapeutic target in bronchiectasis
Source: ERS Lung Science Conference 2020
Year: 2020
RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation
Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept